

Curriculum Vitae

PIGAZZI MARTINA

unique identifier(s): ORCID: 0000-0002-4793-5263; Research ID: K-7997-2016

Date of birth:

Nationality: Italian

e-mail:

• CURRENT POSITIONS

2021-present: Associate Professor (MED-38) University of Padova, Department of Women's and Children's Health, Italy

2018-present: Chief and responsible of the Genetic Unit of the OncoHematology Lab at the University-Hospital of Padova, Department of Women's and Children's Health, Italy.

2013-present: Team Leader at Fondazione Istituto di Ricerca Pediatrica (IRP), "Advance diagnostic and target discovery in AML" laboratory.

2009-present: Chief and responsible of the National reference laboratory for the Associazione Italiana Onco Ematologia Pediatrica (AIEOP) for the molecular diagnosis of pediatric acute myeloid leukemia.

• EDUCATION

2017 National qualification for Associate Professor in Pediatrics (MED-38)

2009 PhD in "Developmental Medicine and Programming science in onco-hematology and immunology", University of Padova, Italy. PhD Supervisor: Prof. G Basso

2004 School of Specialization in Medical Genetic, School of Medicine, University of Verona, Italy. Supervisor: Prof. PF Pignatti

2000 Master Degree in Molecular Biology, University of Padua, Italy. Supervisor Prof. G Valle

• PREVIOUS POSITIONS

2018-present: Assistant Professor (Tenure Track), Department of Women's and Children's Health, University of Padova, Italy

04/09-2018 Visiting scientist at Gene therapy Program at Dana-Farber/Boston Children's Cancer and Blood Disorders Center of Harvard Medical School, Prof. A. Biffi's lab, Boston, USA

2015-2018 Researcher (non-Tenure Track), Onco-Hematology unit, Department of Women's and Children's Health, University of Padova, Italy

2011-2015 Team Leader at Onco-Hematology Lab., Department of Women's and Children's Health, University of Padova, Italy

2010-2011 Post Doctoral fellow in Prof. Giuseppe Basso's Lab. for "Genetic landscape of Acute myeloid leukemia program", Women's and Children's Health, University of Padova. This research activity was conducted in parallel with my welfare activity as geneticist for molecular diagnosis of acute leukemias for the Italian association of onco-hematology (AIEOP).

• INSTITUTIONAL RESPONSIBILITIES

2020 – Steering committee member of the International Leukemia Target Board (iLTB): a concerted action to allocate children, adolescents and young adults with relapsed and refractory leukemia/lymphoma to the right type of therapy: A platform to discuss a rational treatment choice based on molecular, protein and drug response profiling, including a registry.

2020 - board member of Innovative Therapies for Children with Cancer (ITCC-P4) for leukemia patient derived xenograft (PDX) generation entity expert group for liquid tumors

2019 - Consultant of the AIEOP Biology group

2019 - PI of the “Diagnostic” scientific work packages of the “European treatment protocol for children and adolescents with acute myeloid leukemia” (EU-PAL consortium)

2019 - Board member of the AML Data Dictionary-Chicago University - Pediatric Cancer Data Commons - within LLS-PedAL initiative (a global precision medicine master clinical trial that will test multiple targeted therapies simultaneously at up to 200 clinical sites worldwide)

2019 - Chair of the the EU-task-force group “Molecular Genetics of minimal residual disease of AML” for the international Berlin-Frankfurt-Münster (BFM) study group

2018 - Member of the Research Committee of the SDB department, University of Padova, Italy

2018 - Member of the International Committee of the SDB department, University of Padova, Italy

2017 - Member of the Scientific Board of Pediatric Research Institute, Padova, Italy

2014 - Member of the task-force group “Molecular Genetics of minimal residual disease of AML” for the international Berlin-Frankfurt-Münster (BFM) study group

2010 - Delegate for the Italian Association Pediatric Onco-hematology (AIEOP) at the international AML Task Force committee of the international Berlin-Frankfurt-Münster (I-BFM) study group

2010 - Consultant of the AIEOP LANL (acute non lymphoblastic leukemia) group

• FELLOWSHIPS AND PAST FUNDED PROJECTS

2019-2020 Grant: Validation of novel antigenic determinants for the development of a CAR T cell immunotherapy for pediatric acute myeloid leukemia - Funding body: IRP (Synergy Grant); total capital funding: total €400.000, €170.000 as Co-PI to my unit; role: Co-PI with Prof. A.Biffi and Prof. A.Viola.

2018-2020 Grant: Role of bone marrow niche and microenvironment in the acute myeloid leukemia - Funding body: Italian Association against leukaemia lymphomas and myeloma (AIL-TV, Italian Association for Leukemia and Lymphoma section of Treviso); capital funding: €140.000; role: PI

2018/2020 Grant: Development of an optimized preclinical in vivo model for drug discovery in pediatric acute leukemia - Funding body: Fondazione Cariparo; capital funding: €343.300,0; role: PI

2016-2018 Grant: MLL-translocated leukemia in a humanized bone marrow niche: a model for drug screening. Funding body: University of Padova; capital funding: €60.483; role: PI

2009-2011 Post Doctoral Fellow in Prof. G. Basso’s lab, Project: “Role of CREB in acute myeloid leukemia”, University of Padova, Italy

2001-2009 Fellow at Giuseppe Basso’s Lab at Women’s and Children’s Health, University of Padova for several projects regarding acute leukemias diagnosis and research.

• INTELLECTUAL PROPERTY

- Italian patent n°IT102019000015809, 06/09/2019, “Analoghi della tioridazina per trattare la leucemia mieloide” currently under international extension n° PCT/EP2020/074529;

- US patent filed 06/04/2021 “Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens”.

- **AWARDS**

- 2018 Italian Research activity award for “Ricerca e innovazione professione impresa: area oncologica”
- 2017 Posters (two) awarded for the highest scoring abstract at 59th American Society of Hematology (ASH) Congress, Atlanta, USA
- 2016 Poster awarded for the highest scoring abstract at 58th American Society of Hematology (ASH), San Diego, USA
- 2016 Best poster awarded at XXVII iBFM symposium - Athen, Greece.
- 2015 Italian Foundation Marisa Bellisario award: “Padova e i suoi talenti: scienza innovazione e ricerca.” Padova, Italy
- 2015 Best poster awarded at AIEOP National Congress- Lecce, Italy.
- 2014 Poster awarded for the highest scoring abstract at 56th American Society of Hematology (ASH) Congress, San Francisco, USA
- 2014 Award at the 19th European Hematology Association (EHA) Congress, Milano, Italy
- 2013 Poster awarded for the highest scoring abstract at 55th American Society of Hematology (ASH) Congress, New Orleans, USA
- 2010 Poster awarded for the highest scoring abstract at 52nd American Society of Hematology (ASH) Congress, Orlando, USA

- **MENTORSHIP (N° students and post doctoral supervised)**

- 25 undergraduate students of the Schools of Medicine, Nurse, Biology, and Biotechnology;
 - 6 PhD dissertations (Elena Manara, Claudia Tregnago, Sanja Aveic, Valeria Bisio, Giulia Borella, Maddalena Benetton);
 - 8 post-doctoral fellows (Elena Manara, Claudia Tregnago, Sanja Aveic*, Valeria Bisio*, Giulia Borella, Maddalena Benetton, Matteo Zampini*, Francesca Zonta*).
- All the PhD students moved on to a postdoc training; *are running their own labs or independent funded research; underlined one moved to a director position in industry.

- **ACADEMIC TEACHING ACTIVITIES**

- 2021: 40 hours of Pediatrics, Università degli Studi di Padova, Medical School for Nurse - healthcare assistant, Padova, Italy
- 2021 - 20 hours of Pediatrics, Università degli Studi di Padova, Medical School for Neuroscience - healthcare assistant, Padova, Italy
- 2021: 10 hours of Pathology, School of Medical genetics, Università degli Studi di Padova, Medical School of Specialization, Padova, Italy
- 2020 - 20 hours of Pediatrics, Università degli Studi di Padova, Medical School for Nurse - healthcare assistant, Padova, Italy
- 2020 - 20 hours of Pediatrics, Università degli Studi di Padova, Medical School for Neuroscience - healthcare assistant, Padova, Italy
- 2019 - 20 hours of Pediatrics, Università degli Studi di Padova, Medical School for Nurse - healthcare assistant, Padova, Italy.
- 2018 - 20 hours of Pediatrics, Università degli Studi di Padova, Medical School for Nurse - healthcare assistant, Padova, Italy.
- 2017 - 40 hours of Pediatrics, Università degli Studi di Padova, Medical School for Nurse - healthcare assistant, Padova, Italy.
- 2016 - 40 hours of Pediatrics, Università degli Studi di Padova, Medical School for Nurse - healthcare assistant, Padova, Italy.
- 2015 - 4 hours of Oncology in hematology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

2014 - 4 hours at the “Ethics and Biotechnology” Advanced Master at the Università degli Studi di Padova, Italy
2013 - 4 hours at the “Ethics and Biotechnology” Master at the Università degli Studi di Padova, Italy
2011 - 24 hours at the University of Padova, PhD School In Developmental Medicine and Planning Health Sciences, Università degli Studi di Padova, Italy
2010 - 58 hours at the University of Padova, PhD School In Developmental Medicine and Planning Health Sciences, Università degli Studi di Padova, Italy
2009 - 16 hours at the University of Padova, PhD S Developmental Medicine and Planning health science, Università degli Studi di Padova, Italy

- **RECOGNITION AND DIFFUSION ACTIVITY**

Invited oral talks-seminars: 31 (mostly international in ASH, EHA, SIOPe, AACR, I-BFM and AIEOP);

Lay and divulgation activities: for AIEOP since 2010 and I-BFM since 2018;

Ad hoc reviewer: for >10 ISI journals including Leukemia, Haematologica, Pediatric Blood and Cancer, Cancers, British Journal of Hematology, Frontiers, Epigenomics BMC Cancer, PlosOne, Journal of translational medicine, Hematology Oncology, Cell death and differentiation, Pediatric Hematology Oncology; and for major European Funding Agencies including EHA, Swiss Cancer League, ERC-LS4, Cancer Research UK Grants;

Scientific meeting organizer in 2019 the IV Molecular AML meeting for I-BFM, 26-27 March, Padova, Italy; in 2017 the II Molecular AML meeting for I-BFM, 26-27 September, Roma, Italy; from 2014 to 2021 from XX to XXVII AIEOP Winter-InterLab Meetings in Pediatric Hematology-Oncology, Falcade, Belluno, Italy.

-Invited speaker (selected talks in last 5 years)

-2020-10-27 “Impatto della malattia residua minima pre-trapianto sull’outcome dei bambini affetti da leucemia mieloide acuta: uno studio retrospettivo del gruppo di studio i -BFM”, XLV Congresso Nazionale AIEOP VIRTUAL

-2020-01-22 Seminar at Corso Nuovi Farmaci in Oncologia Pediatrica “Quando un target è realmente targetable”, Università degli Studi di Padova, SDB dept., Padova, Italy

-2019-12-09 61st ASH Congress “Acute Myeloid Leukemia (AML) in a 3D Bone Marrow Niche Showed High Performance for in Vitro and In Vivo Drug Screenings”. Orlando, FL

-2019-10-13 XLIV-AIEOP meeting “Studio del ruolo della Malattia Residua Minima Molecolare nei pazienti con leucemia mieloide acuta arruolati nel protocollo LAM2013/01”. Catania, Italy

-2019-05-12 Seminar at BFM international Meeting as Chair of the EU-MRD AML group “Molecular MRD measured before HSCT”. Prague, Czechoslovakia

-2019-01-18 Seminar at Ospedale Pediatrico bambino Gesù “Functional genetic landscape of acute myeloid leukemia: bridging the gap from preclinical modeling to human studies”. Rome, Italy

-2018-05-26 Seminar at V AIEOPINLAB meeting - Disease Modeling section: “Modelli preclinici per l’identificazione di strategie terapeutiche nella Leucemia Mieloide Acuta”, Bologna, Italy

-2018-05-22 11th Biennial Childhood Leukemia and Lymphoma symposium: “Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1 rearranged AML”, Helsinki, Finland

-2018-06-02 Seminar at Salute 4.0 e l’innovazione che parla italiano-Meeting: “Diagnostica avanzata in oncematologia pediatrica”, Farnesina, Roma, Italy

-2018 -23-01 Seminar at Innovabiomed Congress: “La genetica oncologica”, Verona, Italy

-2017-25-10 Seminar at AIEOP Congress - La diagnosi della leucemia acuta ieri oggi domani: “Molecular genetics in AML”, Università degli Studi di Padova, Padova, Italy

-2017-02-06 Seminar at the International BFM study group “Molecular MRD monitoring in

pediatric AML” Meeting: “MRD monitoring in AIEOP”, Aarhus, Denmark
 -2017-02-17 Seminar at Università di Tor Vergata-Rome, Italy: “From molecular markers to functional characterization in pediatric acute myeloid leukemia”
 -2017 -01-02 Seminar at Università degli Studi di Milano-Bicocca, Milano, Italy: “Role of Minimal residual disease in pediatric AML”
 -2016-05-23 XLI Congresso Nazionale AIEOP: “CREB attiva C/EBP δ per indurre la leucemogenesi”, Verona, Italy
 -2016-03-11 Seminar at UnistemDay: “La leucemia mieloide del bambino e le nuove terapie”, Palazzo Bo, Università degli studi di Padova, Padova, Italy

• COMMISSIONS OF TRUST

-2021 - present: Scientific Consultant for Altheia Science srl
 -2020 - present: Editorial Board as Topic Editor of Life Journal
 -2018-09-01 Head of molecular diagnosis for AML-AIEOP patients enrolled in the "Clinical Study-CPKC412A2218 Study: A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3- mutated AML"-Novartis.
 -2015/2018: Scientific Advisory Board-Consultant data monitoring of the committee for the study Protocol AZA-AML-004 DMC by Celgene Pharma
 -2016 - present: Editorial Board Review Editor for the Pediatric Hematology and Hematological Malignancies Journal
 -2014 - present: Editorial Board Review Editor for the of Pediatric Hematology and Immunology Journal
 -2010 - present: Scientific Advisory Board of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
 -2010 - present: Scientific Advisory Board of the Berlin-Frankfurt-Münster (BFM) study group
 -2006 - present: member of the American Association of Cancer Research

• SCIENTIFIC COLLABORATIONS (active projects)

-From 2017: Prof. Silvia Campello e Prof. Francesco Cecconi, Laboratorio di “Mitochondrial Dynamics in AML” - IRCCS Santa Lucia Foundation e Università Tor Vergata-Roma
 -From 2015: Prof. Dirk Reinhardt MD, Ph.D, “PedAML database and several other cooperative-European projects”, Director and Chief of Pediatric Oncology Unit at Universität Duisburg-Essen, Germany
 -From 2014: Prof CM Zwaan, MD Ph.D, “International retrospective study on pediatric AML patients with t(16;21) translocations”, the Pediatric Oncology/Hematology department in Rotterdam and at Princess Máxima Center in Utrecht, The Netherland
 -From 2014: Dr. Tanja Gruber, MD Ph.D, “Sequencing of acute megakaryoblastic leukemia in non-Down syndrome patients and normal karyotype AML”, St. Jude Hospital, Memphis, USA
 -From 2014: Prof. Henrik Hasle “Molecular residual disease in AML”, Department of Clinical Medicine - Department of Paediatrics, Aarhus, Denmark
 -From 2014: Dr. Stefano Cairo, Ph.D, “Development of PDX model in pediatric hepatoblastoma”, Head of Molecular Biology R&D Dept at Xentech, Evry, France
 -From 2014: Dr. Anna Tampieri Ph.D, “Novel 3D scaffolds use for new in vivo AML model”, Head of ISTECC Research group on HTc Superconducting Materials and bioceramics; Institute of Science and Technology for Ceramics (ISTECC-CNR), Faenza, Italy
 -From 2012: Prof. Franco Locatelli, MD Ph.D, “National and international research and clinical projects for the AIEOP-AML group”, University of Rome, Director of the Pediatric Hematology and Oncology Dept., IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy

-From 2011: Prof. Andrea Pession, MD Ph.D, “AML clonal evolution by NGS” University of Bologna, Director of Pediatric Dept. at Ospedale Sant’Orsola, Bologna, Italy

-From 2009: Dr. Dinesh S. Rao, M.D. Ph.D. Assistant Professor; “Assessing the role of linc RNA in leukemia”; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, LA, USA

-From 2008: Prof. Kathleen Sakamoto, M.D., Ph.D; “Role of CREB in AML”; Chief and Director of the Division of Hematology/Oncology Department of Pediatrics, Stanford University School of Medicine, CA, USA

-From 2008: Prof. Andrea Biondi, MD Ph.D, “Molecular diagnostic of AML”, Director of the Physician staff, Pediatric Dept, University of Milan, H.S. Gerardo, Monza, Italy

• CLINICAL ASSISTANCE ACTIVITY

-My hiring for assistance and welfare activity for the Azienda Ospedaliera Padova (AOP) was in 2015 and had the aim of consolidating and implementing the diagnostic activity in the field of genetics of pediatric acute leukemias, with particular attention to acute myeloid leukemia. My assistance activity takes place at the Onco-Hematology laboratory of the Department of Women's and Children's Health, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation of the University and Hospital of Padova, which serves as a reference laboratory of the Italian Association of Pediatric Hemato-Oncology (AIEOP) group for the diagnosis of pediatric leukemias, lymphomas and solid tumors. I am specialist in medical genetics and the head of the Genetics Unit of our laboratory for this reason I take care of the supervision and reporting of all the genetic screenings that are performed in our laboratory to diagnose both malignant diseases (acute or chronic leukemia, myeloproliferative or myelodysplastic syndromes), hematological benign pathologies or at risk of malignant evolution (anemias, hypereosinophilia, thrombocythemias, and other suspected or not better defined hematological disorders that go into differential diagnosis with malignant pathologies). I provide genetic counseling and reports also in samples collected during treatment at the follow-up by performing the study of minimal molecular residual disease. Further, in the last two years the genetic diagnosis activity is also performed for those hereditary defects of immunity or primary immunodeficiencies (IDPs) which are a heterogeneous group of diseases of the immune system caused by monogenic defects and clinically characterized by increased susceptibility to infections, autoimmunity, autoinflammation, allergy and predisposition to neoplastic pathologies. This activity is performed for all cases that arrive at our center as well as from external requests from other AOP-units or other Hospitals-Academia in the whole Italy.

-My activity as a geneticist is nationally recognized as being responsible for the molecular diagnostics of patients enrolled in the last concluded clinical study AML2002/01 and in the ongoing AML2013/01 (in progress-EudraCT 2014-000652-28) of patients affected by acute myeloid leukemia sponsored by the Associazione Italiana Emato-Oncologia Pediatrica (AIEOP). The trial is based on genetic stratification since diagnosis for a tailored adopted therapy strategy. For the 58 centers-hospitals that belong to the AIEOP groups and enroll patients in AIEOP trials, I provide genetic counseling and reports, arriving as external requests to AOP, for samples at diagnosis and during treatment by performing the study of minimal molecular residual disease analyses.

-Genetic diagnosis are performed by using RT-PCR and/or by by Next generation platform (Invitae or Illumina technologies) by using targeted commercial or customized NGS panels for selected genes being reported for their recurrent involvement cancer, myeloid diseases, or predisposition cancer genes.

*Molecular MRD tests have been set up to a large extent in compliance with the Europe Against Cancer (EAC) protocols. The Eu- TaqMan® qPCR based MRD assay (and preparatory steps) detects and quantify selected mutations and fusion transcripts characteristic of pediatric AML.

• **ACTIVE GRANTS OWNER**

On-going Grants:

<i>Project Title</i>	<i>Funding source</i>	<i>Amount (Euros)</i>	<i>Period</i>	<i>Role of the PI</i>
Integrative approach to decode the leukemic niche electrical communication patterns to ease advances in pediatric treatment opportunities	Pediatric Research Institute (IRP)	€326.000	2021-2023	PI
Ruolo della nicchia midollare nella leucemia acuta pediatrica	AIL-TREVISO	210.000	2021-2023	PI
NOVEL ANTIGENIC DETERMINANTS for the development of a CAR T CELL immunotherapy for pediatric ACUTE MYELOID LEUKEMIA	Industrial funding (Altheia Science) in alliance with University of Padova	€850.000	2021-2023	Co-PI
ChiLTERN-Children's Liver Tumour European Research Network	H2020-PHC-18-2015 (GAN.T-668596)	€130.000	2018-2022	WP3 Co-Leader
Clinical Study-CPKC412A2218 Study: A phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AML.	Novartis	60.000/year	2019-2021	PI
Adoptive Chimeric Antigen Receptor cell therapy for the treatment of patients with Acute Myeloid Leukemia: Development of preclinical models to assess efficacy and safety	Italian Ministry of Health: Prot. 2020N4S3FA	To my unit €260.000	2022/202	Co-PI

Development of innovative preclinical tools for an effective therapeutic strategy in pediatric acute myeloid leukemia AIRC, -IG2017 Project n. 20562	Italian Association for Cancer Research (AIRC)	€608.000	2018-2022	PI
--	--	----------	-----------	----

• **LIST OF PUBLICATIONS**

1. Porcù E, Benetton M, Bisio V, Da Ros A, Tregnago C, Borella G, Zanon C, Bordi M, Germano G, Manni S, Campello S, Rao DS, Locatelli F, Pigazzi M. The long non-coding RNA *CDK6-AS1* overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics. *iScience*. 2021 Oct 26;24(11):103350. doi: 10.1016/j.isci.2021.103350.
2. Fornerod M, Ma J, Noort S, Liu Y, Walsh MP, Shi L, Nance S, Liu Y, Wang Y, Song G, Lamprecht T, Easton J, Mulder HL, Yergeau D, Myers J, Kamens JL, Obeng EA, Pigazzi M, Jarosova M, Kelaidi C, Polychronopoulou S, Lamba JK, Baker SD, Rubnitz JE, Reinhardt D, van den Heuvel-Eibrink MM, Locatelli F, Hasle H, Klco JM, Downing JR, Zhang J, Pounds S, Zwaan CM, Gruber TA; Berlin-Frankfurt-Munster Study Group (BFM); Dutch Children's Oncology Group (DCOG); Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP); Nordic Society for Pediatric Hematology and Oncology (NOPHO); Dutch Children's Oncology Group (DCOG); for St. Jude Children's Research Hospital Study Group (SJCRH). Integrative Genomic analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. *Blood Cancer Discov*. 2021 Sep 9;2(6):586-599. doi: 10.1158/2643-3230.BCD-21-0049. PMID: 34778799; PMCID: PMC8580615.
3. Mariotto E, Corallo D, Pantile M, Giarin E, Pigazzi M, Basso G, Viola G, Aveic S. BAG1 down-regulation increases chemo-sensitivity of acute lymphoblastic leukaemia cells. *J Cell Mol Med*. 2021 Sep;25(18):9060-9065. doi: 10.1111/jcmm.16822. Epub 2021 Aug 17. PMID: 34402163; PMCID: PMC8435410.
4. Tregnago C, Benetton M, Padrin D, Polato K, Borella G, Da Ros A, Marchetti A, Porcù E, Del Bufalo F, Mecucci C, Locatelli F, Pigazzi M. NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML. *Cancers (Basel)*. 2021 Jul 10;13(14):3457. doi: 10.3390/cancers13143457. PMID: 34298672; PMCID: PMC8304368.
5. Giulia Borella, Ambra Da Ros, Giulia Borile, Elena Porcù, Claudia Tregnago, Maddalena Benetton, Anna Marchetti, Valeria Bisio, Barbara Montini, Barbara Michielotto, Alice Cani, Anna Leszl, Elisabetta Campodoni, Monica Sandri, Monica Montesi, Silvia Bresolin, Stefano Cairo, Barbara Buldini, Franco Locatelli, Martina Pigazzi*. Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course. *BLD-2020-009845R2 in press, see letter of acceptance 20/04/2021*

6. Zangrando A, Cavagnero F, Scarparo P, Varotto E, Francescato S, Tregnago C, Cuccurullo R, Fagioli F, Nigro LL, Masetti R, Putti MC, Rizzari C, Santoro N, Pession A, Pigazzi M, Locatelli F, Basso G, Buldini B. CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript. *Cytometry A*. 2021 Apr 2. doi: 10.1002/cyto.a.24339. Online ahead of print. PMID: 33811445.
7. Masetti R, Pigazzi M, Zama D. Editorial: New Perspectives on Pediatric Acute Leukemia. *Front Pediatr*. 2020 Dec 7;8:618426. doi: 10.3389/fped.2020.618426. PMID: 33365293; PMCID: PMC7750355. IF 2.634
8. Zubovic L, Piazza S, Tebaldi T, Cozzuto L, Palazzo G, Sidarovich V, De Sanctis V, Bertorelli R, Lammens T, Hofmans M, De Moerloose B, Ponomarenko J, Pigazzi M, Masetti R, Mecucci C, Basso G, Macchi P. The altered transcriptome of pediatric myelodysplastic syndrome revealed by RNA sequencing. *J Hematol Oncol*. 2020 Oct 12;13(1):135. doi: 10.1186/s13045-020-00974-3. PMID: 33046098; PMCID:PMC7552545. IF 11.059
9. Tregnago C, Da Ros A, Porcù E, Benetton M, Simonato M, Simula L, Borella G, Polato K, Minuzzo S, Borile G, Cogo P, Campello S, Massi A, Romagnoli R, Buldini B, Locatelli F, Pigazzi M. Thioridazine requires calcium influx to induce MLL- AF6-rearranged AML cell death. *Blood Adv*. 2020 Sep 22;4(18):4417-4429. doi:10.1182/bloodadvances.2020002001. PMID: 32931582; PMCID: PMC7509857. IF 4.584
10. Chae HD, Dutta R, Tiu B, Hoff FW, Accordi B, Serafin V, Youn M, Huang M, Sumarsono N, Davis KL, Lacayo NJ, Pigazzi M, Horton TM, Kornblau SM, Sakamoto KM. RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. *Oncotarget*. 2020 Jun 23;11(25):2387-2403. doi:10.18632/oncotarget.27630. PMID: 32637030; PMCID: PMC7321696.
11. Simula L, Corrado M, Accordi B, Di Rita A, Nazio F, Antonucci Y, Di Daniele, A, Caicci F, Caruana I, Soriano ME, Pigazzi M, Locatelli F, Cecconi F, Campello S. JNK1 and ERK1/2 modulate lymphocyte homeostasis via BIM and DRP1 upon AICD induction. *Cell Death Differ*. 2020 Oct;27(10):2749-2767. doi:10.1038/s41418-020-0540-1. Epub 2020 Apr 28. Erratum in: *Cell Death Differ*. 2020 Jul 20;: PMID: 32346136; PMCID: PMC7492225. IF 10.717
12. Borile G, Rossi S, Filippi A, Gazzola E, Capaldo P, Tregnago C, Pigazzi M, Romanato F. Label-free, real-time on-chip sensing of living cells via grating- coupled surface plasmon resonance. *Biophys Chem*. 2019 Nov;254:106262. doi: 10.1016/j.bpc.2019.106262. Epub 2019 Sep 3. PMID: 31514114. IF 1.995
13. Simula L, Pacella I, Colamatteo A, Procaccini C, Cancila V, Bordi M, Tregnago C, Corrado M, Pigazzi M, Barnaba V, Tripodo C, Matarese G, Piconese S, Campello S. Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming. *Cell Rep*. 2018 Dec 11;25(11):3059-3073.e10. doi: 10.1016/j.celrep.2018.11.018. PMID:30540939; PMCID: PMC6302735. IF 8.109
14. Noort S, Zimmermann M, Reinhardt D, Cuccuini W, Pigazzi M, Smith J, Ries RE, Alonzo TA, Hirsch B, Tomizawa D, Locatelli F, Gruber TA, Raimondi S, Sonneveld E, Cheuk DK, Dworzak M, Stary J, Abrahamsson J, Arad-Cohen N, Czogala M, De Moerloose B, Hasle H, Meshinchi S, van den Heuvel-Eibrink M, Zwaan CM. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: aretrospective study by the I-BFM Study Group. *Blood*. 2018 Oct 11;132(15):1584-1592. doi: 10.1182/blood-2018-05-849059. Epub 2018 Aug 27. PMID:30150206; PMCID: PMC6265640. IF 17.543
15. Zampini M, Tregnago C, Bisio V, Simula L, Borella G, Manara E, Zanon C, Zonta F, Serafin V, Accordi B, Campello S, Buldini B, Pession A, Locatelli F, Basso G, Pigazzi M. Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. *Leukemia*. 2018 May;32(5):1124-1134. doi: 10.1038/s41375-017-0003-y. Epub 2018 Feb 2. PMID:29472719. IF 8.665
16. Zampini M, Bisio V, Leszl A, Putti MC, Menna G, Rizzari C, Pession A, Locatelli F, Basso G, Tregnago C, Pigazzi M. A three-miRNA-based expression signature at diagnosis can

- predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia. *Br J Haematol.* 2018 Oct;183(2):298-301. doi: 10.1111/bjh.14950. Epub 2017 Sep 29. PMID: 28961307. IF 5.518
17. Fernando TR, Contreras JR, Zampini M, Rodriguez-Malave NI, Alberti MO, Anguiano J, Tran TM, Palanichamy JK, Gajeton J, Ung NM, Aros CJ, Waters EV, Casero D, Basso G, Pigazzi M, Rao DS. The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. *Mol Cancer.* 2017 Jul 19;16(1):126. doi: 10.1186/s12943-017-0692-x. PMID: 28724437; PMCID: PMC5517805. Molecular Cancer IF 15.302
 18. Germano G, Morello G, Aveic S, Pinazza M, Minuzzo S, Frasson C, Persano L, Bonvini P, Viola G, Bresolin S, Tregnago C, Paganin M, Pigazzi M, Indraccolo S, Basso G. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia. *Oncotarget.* 2017 Apr 18;8(16):26129-26141. doi:10.18632/oncotarget.15387. PMID: 28412727
 19. Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C, Putti MC, Rizzari C, Santoro N, Zecca M, Disarò S, Rondelli R, Merli P, Pigazzi M, Pession A, Locatelli F, Basso G. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. *Br J Haematol.* 2017 Apr;177(1):116-126. doi: 10.1111/bjh.14523. Epub 2017 Feb 27. PMID: 28240765. IF 5.518
 20. de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, Obulkasim A, Dang J, Easton J, Verboon LJ, Mulder HL, Zimmermann M, Koss C, Gupta P, Edmonson M, Rusch M, Lim JY, Reinhardt K, Pigazzi M, Song G, Yeoh AE, Shih LY, Liang DC, Halene S, Krause DS, Zhang J, Downing JR, Locatelli F, Reinhardt D, van den Heuvel-Eibrink MM, Zwaan CM, Fornerod M, Gruber TA. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. *Nat Genet.* 2017 Mar;49(3):451-456. doi: 10.1038/ng.3772. Epub 2017 Jan 23. PMID: 28112737. IF 27.603
 21. Masetti R, Bertuccio SN, Astolfi A, Chiarini F, Lonetti A, Indio V, De Luca M, Bandini J, Serravalle S, Franzoni M, Pigazzi M, Martelli AM, Basso G, Locatelli F, Pession A. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. *J Hematol Oncol.* 2017 Jan 21;10(1):26. doi:10.1186/s13045-017-0396-0. PMID: 28109323; PMCID: PMC5251306. IF 11.059
 22. Bisio V, Zampini M, Tregnago C, Manara E, Salsi V, Di Meglio A, Masetti R, Togni M, Di Giacomo D, Minuzzo S, Leszl A, Zappavigna V, Rondelli R, Mecucci C, Pession A, Locatelli F, Basso G, Pigazzi M. NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. *Leukemia.* 2017 Apr;31(4):974-977. doi:10.1038/leu.2016.361. Epub 2016 Nov 28. PMID: 27890935. IF 8.665
 23. Masetti R, Castelli I, Astolfi A, Bertuccio SN, Indio V, Togni M, Belotti T, Serravalle S, Tarantino G, Zecca M, Pigazzi M, Basso G, Pession A, Locatelli F. Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. *Oncotarget.* 2016 Aug 30;7(35):56746-56757. doi: 10.18632/oncotarget.10778. PMID: 27462774.
 24. Manara E, Basso G, Zampini M, Buldini B, Tregnago C, Rondelli R, Masetti R, Bisio V, Frison M, Polato K, Cazzaniga G, Menna G, Fagioli F, Merli P, Biondi A, Pession A, Locatelli F, Pigazzi M. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. *Leukemia.* 2017 Jan;31(1):18-25. doi: 10.1038/leu.2016.177. Epub 2016 Jun 28. PMID:27416911. IF 8.665
 25. Paganin M, Buldini B, Germano G, Segnanfreddo E, Meglio Ad, Magrin E, Grillo F, Pigazzi M, Rizzari C, Cazzaniga G, Khiabani H, Palomero T, Rabadan R, Ferrando AA, Basso G. A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. *Pediatr Blood Cancer.* 2016 Sep;63(9):1660-3. doi: 10.1002/pbc.26054. Epub 2016 May 3. PMID: 27149388. IF 2.335
 26. Tregnago C, Manara E, Zampini M, Bisio V, Borga C, Bresolin S, Aveic S, Germano G, Basso G, Pigazzi M. CREB engages C/EBP δ to initiate leukemogenesis. *Leukemia.* 2016

- Sep;30(9):1887-96. doi:10.1038/leu.2016.98. Epub 2016 Apr 27. PMID: 27118402.IF 8.665
27. de Rooij JD, Masetti R, van den Heuvel-Eibrink MM, Cayuela JM, Trka J, Reinhardt D, Rasche M, Sonneveld E, Alonzo TA, Fornerod M, Zimmermann M, Pigazzi M, Pieters R, Meshinchi S, Zwaan CM, Locatelli F. Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. *Blood*. 2016 Jun 30;127(26):3424-30. doi: 10.1182/blood-2016-01-695551.Epub 2016 Apr 25. PMID: 27114462.IF 17.543
 28. Palanichamy JK, Tran TM, Howard JM, Contreras JR, Fernando TR, Sterne-Weiler T, Katzman S, Toloue M, Yan W, Basso G, Pigazzi M, Sanford JR, Rao DS. RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. *J Clin Invest*. 2016 Apr 1;126(4):1495-511. doi: 10.1172/JCI80046. Epub 2016 Mar 14. PMID: 26974154. IF 11.864
 29. Togni M, Masetti R, Pigazzi M, Astolfi A, Zama D, Indio V, Serravalle S, Manara E, Bisio V, Rizzari C, Basso G, Pession A, Locatelli F. Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing. *J Hematol Oncol*. 2015 Jun 12;8:69.doi: 10.1186/s13045-015-0167-8. PMID: 26066811; PMCID: PMC4467064. IF 11.059
 30. Fernando TR, Rodriguez-Malave NI, Waters EV, Yan W, Casero D, Basso G, Pigazzi M, Rao DS. LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia. *Mol Cancer Res*. 2015 May;13(5):839-51. doi: 10.1158/1541-7786.MCR-15-0006-T. Epub 2015 Feb 13. PMID: 25681502; PMCID: PMC4433429. IF 4.630
 31. Pigazzi M, Manara E, Buldini B, Beqiri V, Bisio V, Tregnago C, Rondelli R, Masetti R, Putti MC, Fagioli F, Rizzari C, Pession A, Locatelli F, Basso G. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. *Haematologica*. 2015 Mar;100(3):e99-101. doi:10.3324/haematol.2014.114579. Epub 2014 Dec 5. PMID: 25480496; PMCID:PMC4349288.IF 7.116
 32. Aveic S, Viola G, Accordi B, Micalizzi C, Santoro N, Masetti R, Locatelli F, Basso G, Pigazzi M. Targeting BAG-1: a novel strategy to increase drug efficacy in acute myeloid leukemia. *Exp Hematol*. 2015 Mar;43(3):180-190.e6. doi: 10.1016/j.exphem.2014.10.016. Epub 2014 Nov 11. PMID: 25461257.IF 2.820
 33. Masetti R, Rondelli R, Fagioli F, Mastronuzzi A, Pierani P, Togni M, Menna G, Pigazzi M, Putti MC, Basso G, Pession A, Locatelli F. Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. *Haematologica*. 2014 Aug;99(8):e127-9. doi: 10.3324/haematol.2014.106526. Epub 2014 May 16. PMID: 24837468; PMCID:PMC4116842. IF 7.116
 34. Manara E, Baron E, Tregnago C, Aveic S, Bisio V, Bresolin S, Masetti R, Locatelli F, Basso G, Pigazzi M. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. *Blood*. 2014 Jul 10;124(2):263-72. doi: 10.1182/blood-2013-09-525741. Epub 2014 Apr 2. PMID:24695851.IF 17.543
 35. Masetti R, Togni M, Astolfi A, Pigazzi M, Indio V, Rivalta B, Manara E, Rutella S, Basso G, Pession A, Locatelli F. Whole transcriptome sequencing of a paediatric case of de novo acute myeloid leukaemia with del(5q) reveals RUNX1-USP42 and PRDM16-SKI fusion transcripts. *Br J Haematol*. 2014 Aug;166(3):449-52. doi: 10.1111/bjh.12855. Epub 2014 Mar 27. PMID: 24673627.IF 5.518
 36. Manara E, Bisio V, Masetti R, Beqiri V, Rondelli R, Menna G, Micalizzi C, Santoro N, Locatelli F, Basso G, Pigazzi M. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations. *Leukemia*. 2014 May;28(5):1132-4. doi: 10.1038/leu.2013.339. Epub 2013 Nov 14. PMID: 24226631.IF 8.665

37. Masetti R, Togni M, Astolfi A, Pigazzi M, Manara E, Indio V, Rizzari C, Rutella S, Basso G, Pession A, Locatelli F. DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia. *Oncotarget*. 2013 Oct;4(10):1712-20. doi:10.18632/oncotarget.1280. PMID: 24127550; PMCID: PMC3858557.
38. Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, Luciani M, Lo Nigro L, Menna G, Micalizzi C, Santoro N, Testi AM, Zecca M, Biondi A, Pigazzi M, Rutella S, Rondelli R, Basso G, Locatelli F; AIEOP AML Study Group. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. *Blood*. 2013 Jul 11;122(2):170-8. doi:10.1182/blood-2013-03-491621. Epub 2013 May 14. PMID: 23673857. IF 17.543
39. Masetti R, Pigazzi M, Togni M, Astolfi A, Indio V, Manara E, Casadio R, Pession A, Basso G, Locatelli F. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. *Blood*. 2013 Apr 25;121(17):3469-72. doi:10.1182/blood-2012-11-469825. Epub 2013 Feb 13. PMID: 23407549. IF 17.543
40. Pigazzi M, Manara E, Bisio V, Aveic S, Masetti R, Menna G, Zecca M, Pession A, Locatelli F, Basso G. Screening of novel genetic aberrations in pediatric acute myeloid leukemia: a report from the AIEOP AML-2002 study group. *Blood*. 2012 Nov 1;120(18):3860-2. doi: 10.1182/blood-2012-09-454454. PMID:23118215. IF 17.543
41. Pigazzi M, Manara E, Bresolin S, Tregnago C, Beghin A, Baron E, Giarin E, Cho EC, Masetti R, Rao DS, Sakamoto KM, Basso G. MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation. *Haematologica*. 2013 Apr;98(4):602-10. doi:10.3324/haematol.2012.070664. Epub 2012 Oct 25. PMID: 23100280; PMCID:PMC3659992. IF 7.116
42. Sandoval S, Kraus C, Cho EC, Cho M, Bies J, Manara E, Accordi B, Landaw EM, Wolff L, Pigazzi M, Sakamoto KM. Sox4 cooperates with CREB in myeloid transformation. *Blood*. 2012 Jul 5;120(1):155-65. doi:10.1182/blood-2011-05-357418. Epub 2012 May 24. PMID: 22627767; PMCID:PMC3390953. IF 17.543
43. Pigazzi M, Masetti R, Martinolli F, Manara E, Beghin A, Rondelli R, Locatelli F, Fagioli F, Pession A, Basso G. Presence of high-ERG expression is an independent unfavorable prognostic marker in MLL-rearranged childhood myeloid leukemia. *Blood*. 2012 Jan 26;119(4):1086-7; author reply 1087-8. doi:10.1182/blood-2011-10-385815. PMID: 22282493. IF 17.543
44. Aveic S, Pigazzi M, Basso G. BAG1: the guardian of anti-apoptotic proteins in acute myeloid leukemia. *PLoS One*. 2011;6(10):e26097. doi:10.1371/journal.pone.0026097. Epub 2011 Oct 10. PMID: 22016818; PMCID:PMC3189928. IF 2.740
45. Paganin M, Pigazzi M, Bresolin S, Masetti R, Fagioli F, Chiaretti S, Cazzaniga G, Locatelli F, Pession A, te Kronnie G, Basso G. DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study. *Haematologica*. 2011Dec;96(12):1886-7. doi: 10.3324/haematol.2011.049825. Epub 2011 Aug 31. PMID: 21880635; PMCID: PMC3232276. IF 7.116
46. Pigazzi M, Masetti R, Bresolin S, Beghin A, Di Meglio A, Gelain S, Trentin L, Baron E, Giordan M, Zangrando A, Buldini B, Leszl A, Putti MC, Rizzari C, Locatelli F, Pession A, Te Kronnie G, Basso G. MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. *Leukemia*. 2011 Mar;25(3):560-3. doi:10.1038/leu.2010.316. Epub 2011 Feb 18. PMID: 21331072. IF 8.665
47. Pigazzi M, Manara E, Beghin A, Baron E, Tregnago C, Basso G. ICER evokes Dusp1-p38 pathway enhancing chemotherapy sensitivity in myeloid leukemia. *Clin Cancer Res*. 2011 Feb 15;17(4):742-52. doi: 10.1158/1078-0432.CCR-10-0886. PMID:21325296. IF 10.107
48. Pigazzi M, Ferrari G, Masetti R, Falini B, Martinolli F, Basso G, Biondi A, Pession A, Cazzaniga G. Low prevalence of IDH1 gene mutation in childhood AML in Italy.

- Leukemia. 2011 Jan;25(1):173-4. doi: 10.1038/leu.2010.229. Epub 2010 Oct 14. PMID: 20944672.IF 8.665
49. Sandoval S, Pigazzi M, Sakamoto KM. CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. *Adv Hematol.* 2009;2009:634292. doi: 10.1155/2009/634292. Epub 2009 Aug 27. PMID: 19960054; PMCID: PMC2778441. IF 0.516
 50. Bonvini P, Zorzi E, Mussolin L, Monaco G, Pigazzi M, Basso G, Rosolen A. The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. *Haematologica.* 2009 Jul;94(7):944-55. doi:10.3324/haematol.2008.004861. Epub 2009 Jun 16. PMID: 19535344; PMCID:PMC2704305.IF 7.116
 51. Pigazzi M, Manara E, Baron E, Basso G. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. *Cancer Res.* 2009 Mar 15;69(6):2471-8. doi: 10.1158/0008-5472.CAN-08-3404. Epub 2009 Mar 3. PMID:19258499.IF 9.727
 52. Pigazzi M, Manara E, Baron E, Basso G. ICER expression inhibits leukemia phenotype and controls tumor progression. *Leukemia.* 2008 Dec;22(12):2217-25. doi: 10.1038/leu.2008.244. Epub 2008 Sep 11. PMID:18784739.IF 8.665
 53. Pigazzi M, Ricotti E, Germano G, Faggian D, Aricò M, Basso G. cAMP response element binding protein (CREB) overexpression CREB has been described as critical for leukemia progression. *Haematologica.* 2007 Oct;92(10):1435-7. doi:10.3324/haematol.11122. PMID: 18024382.IF 7.116
 54. Germano G, Pigazzi M, del Giudice L, Campo Dell'Orto M, Spinelli M, Zangrando A, Paolucci P, Ladogana S, Basso G. Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia. *Haematologica.* 2006 May;91(5 Suppl):ECR09. PMID: 16709517.IF 7.116
 55. Frascella E, Rondelli R, Pigazzi M, Zampieron C, Fagioli F, Favre C, Lippi AA, Locatelli F, Luciani M, Menna G, Micalizzi C, Rizzari C, Testi AM, Pession A, Basso G. Clinical features of childhood acute myeloid leukaemia with specific gene rearrangements. *Leukemia.* 2004 Aug;18(8):1427-9. doi:10.1038/sj.leu.2403410. PMID: 15201852.IF 8.665

Padova, 31/01/2022